---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093298"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:51:57.638067+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences reports Q2 2024 net loss of $20.3M; cash $187.4M into H2 2026

## Summary
- Net loss of $20.3M in Q2 2024 vs $18.3M in Q2 2023; R&D spend $16.9M, G&A $5.9M.
- Cash and marketable securities $187.4M as of June 30, 2024; expected to fund operations into H2 2026.
- Phase 3 CoMpass trial for small choroidal melanoma continues enrollment globally; target ~100 patients.
- Early NMIBC Phase 1 data expected at virtual urologic oncology event in October 2024.
- Phase 2 end-of-study data in small choroidal melanoma at Retina Society Annual Meeting Sept 2024.

## SEC filing metadata
- accession: 0000950170-24-093298
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000095017024093298/0000950170-24-093298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000095017024093298/aura-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093298
- JSON: https://secwatch.observer/filing/0000950170-24-093298.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093298.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.